Voyager Therapeutics announces data from SAD trial of VY7523
Voyager Therapeutics (VYGR) announced positive topline data from the Company’s single ascending dose, SAD, trial of VY7523, an investigational ...
Nasdaq3d
Voyager Therapeutics Reports Positive Topline Data for VY7523 in Alzheimer’s Disease Trials
Voyager Therapeutics announced positive results from the single ascending dose (SAD) trial of its investigational anti-tau antibody, VY7523, which demonstrates safety, tolerability, and dose ...
Nasdaq3d
Voyager Therapeutics Reports Positive Data From Single Ascending Dose Study Of VY7523
(RTTNews) - Voyager Therapeutics, Inc. (VYGR) Monday announced positive topline data from its single ascending dose (SAD) study of VY7523 developed for the treatment of Alzheimers disease (AD).
Investing3d
Voyager reports positive early data in Alzheimer's study
VY7523 is designed as an intravenous anti-tau antibody to selectively inhibit the spread of pathological tau, a protein linked to disease progression and cognitive decline in Alzheimer's.
Voyager reports promising data for early stage trial in Alzheimer’s disease treatment
Voyager Therapeutics (VYGR) said on Monday that the company provided positive topline data from its early stage trial of VY7523, an antibody to selectively inhibit the spread of pathological tau in ...
Investing3d
Voyager reports positive early data in Alzheimer’s study
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a biotech firm focusing on neurogenetic medicines, has announced encouraging preliminary results from a clinical trial of its Alzheimer’s ...
Yahoo Finance2d
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter. The mysteries of Alzheimer’s disease are unfolding ...